Detection of alpha-methylacyl-CoA racemase (AMACR) A biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor

Po Yuan Lin, Kai Lun Cheng, James D. McGuffin-Cawley, Fuh Sheng Shieu, Anna C. Samia, Sanjay Gupta, Matthew Cooney, Cheryl L. Thompson, Chung Chiun Liu

研究成果: 雜誌貢獻期刊論文同行評審

21 引文 斯高帕斯(Scopus)

摘要

Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive andindolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis.

原文???core.languages.en_GB???
頁(從 - 到)377-387
頁數11
期刊Biosensors
2
發行號4
DOIs
出版狀態已出版 - 12月 2012

指紋

深入研究「Detection of alpha-methylacyl-CoA racemase (AMACR) A biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor」主題。共同形成了獨特的指紋。

引用此